Screener Summaries Updates Institutions Sign In More Updates › Other Events › DFTX Other Events · Jun 22, 2026
Definium Therapeutics, Inc. announced positive topline data from its Phase 3 Emerge study of DT120 ODT for the… DFTX Definium Therapeutics, Inc.
Definium Therapeutics, Inc. announced positive topline data from its Phase 3 Emerge study of DT120 ODT for the treatment of major depressive disorder. The company released a press release and a presentation discussing the results of the study. Definium Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for mental health disorders.
More from Definium Therapeutics, Inc. Definium Therapeutics announced positive topline results from the Phase 3 Panorama study of DT120 ODT for generalized… Sep 14, 2026 On September 8, 2026, Definium Therapeutics announced that the U.S. Food and Drug Administration granted Breakthrough… Sep 8, 2026 Definium Therapeutics, Inc. entered into an underwriting agreement on June 23, 2026, for a public offering of… Jun 24, 2026 On June 11, 2026, Definium Therapeutics, Inc. held its Annual General and Special Meeting of Shareholders Jun 12, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
